A groundbreaking late-stage study highlights the effectiveness of Viridian Therapeutics' novel treatment, veligrotug, for chronic thyroid eye disease, offering hope for more convenient and efficient therapy. Positive results led to a substantial boost in the company's stock price.
Bausch + Lomb, a major eye-care company, is exploring a potential sale in response to a request from the Canadian Investment Regulatory Organization (CIRO) due to media reports on likely sale triggering volatility in its shares.
Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.
In a stark reflection of diabetes screening gaps, more than one-quarter of U.S. adults with diabetes remained undiagnosed in 2021-2023, with obesity linked to a nearly four-fold higher prevalence compared to normal-weight individuals.
Judge rules in favor of AHA, declaring HHS's online tracking restrictions unlawful, impacting hospitals' use of web technologies for health information sharing.